Skip to main content

Table 4 Quality of evidence of the reviews included according to GRADE

From: Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews

 

Impact

Confidence

Importance

No. studies

Study design

Risk of Bias

Inconsistency

Indirect evidence

Imprecision

Other considerations

  

Pain

 8

SR of CT

Not serious

Serious a

Not serious

Not serious

Highly suspicious

Favors AMT

++

Low

Critical

Sleep

 6

SR of CT

Not serious

Serious a

Not serious

Not serious

None

Favors AMT

+++

Moderate

Critical

Fatigue

 7

SR of CT

Not serious

Not serious

Not serious

Not serious

Highly-suspicious publication bias

Favors AMT

+++

Moderate

Critical

Mood Disorder

 4

SR of CT

Not serious

Not serious

Not serious

Not serious

None

Favors DLX

++++

High

Critical

Quality of life

 5

SR of CT

Not serious

Not serious

Not serious

Not serious

None

Favors AMT

++++

High

Critical

Safety and acceptability

 7

SR of CT

Not serious

Serious b

Not serious

Not serious

Highly suspicious publication bias

DLX with higher acceptability and safety for elderlies; AMT with higher safety for non-elderlies

++

Low

Critical

  1. SR Systematic Review, CT Clinical Trial; a most of the reviews do no detail the results of the heterogeneity tests and, in some of them, the rates were high; b diverging results with rare approaches to explain heterogeneity; scarce safety data; AMT Amitriptyline, DLX Duloxetine